^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    5P12-RANTES

    i
    Other names: 5P12-RANTES, OB-002, OB 002, OB-002C, OB-002M, OB-002O
    Associations

    News

    Trials
    Company:
    Orion Biotech
    Drug class:
    CCR5 receptor antagonist
    Related drugs:
    Associations

    News

    Trials
    8ms
    Study of OB-002 in Patients With Refractory Metastatic Cancer (clinicaltrials.gov)
    P1, N=0, Withdrawn, Orion Biotechnology Polska Sp. z o.o. | Phase classification: P1b --> P1 | N=36 --> 0 | Not yet recruiting --> Withdrawn
    Phase classification • Enrollment change • Trial withdrawal
    |
    5P12-RANTES
    over2years
    Study of OB-002 in Patients With Refractory Metastatic Cancer (clinicaltrials.gov)
    P1b, N=36, Not yet recruiting, Orion Biotechnology Polska Sp. z o.o.
    New P1 trial • Metastases
    |
    5P12-RANTES